The purpose of this study was to develop a simple diagnostic system for TP53 signature using multiplex reverse transcription–polymerase chain reaction (RT–PCR), to test its diagnostic precision and prognostic predictability in a prospective cohort and to examine the clinical significance of TP53 signature among breast cancer subtypes. This evidence concerns the gene TP53 and breast carcinoma.